The Effectiveness of Preemptive Nebulized Dexamethasone in Reducing Post- Operative Sore Throat Following the Use of AMBU® AURAGAINTM Device: A Double Blind, Randomised Clinical Trial

USM/JEPeM/19120934

This study aims to study the effectiveness of preoperatively nebulized dexamethasone in reducing the incidence and severity of Post Operative Sore Throat, POST in patients undergoing surgery under general anesthesia using the Ambu® AuraGainTM SGA device, with secondary aims of determining the effectiveness of dexamethasone in reducing post-operative cough severity and hoarseness of voice

2020-12-01

2021-12-31

2021-12-31

Completed

140

Inclusion Criteria: * Between the ages of 18-70 years * American Society of Anaesthesiology (ASA) physical status of 1 and 2 * Patients undergoing elective procedures under general anaesthesia between the data collection period suitable for SGA device Exclusion Criteria: * Pre-existing sore throat/hoarseness on pre-operative assessment * Patients with history of postoperative nausea or vomiting * Recent (2 weeks) upper or lower respiratory tract infection * Known hypersensitivity to dexamethasone or on regular steroids * Uncontrolled diabetes of capillary blood sugar more than 10mmol/l on pre-operative assessment * Morbidly obese with BMI \> 40 kg/m2 * Procedure exceeding 3 hours duration * Procedure requiring prone or Trendelenburg position or manipulation of head post-induction * Oral and neck surgeries * Pregnant patients * Patients with cognitive disabilities * Patients requiring nasogastric tube or nasal temperature probe insertion * Patient refusal

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 140, 'type': 'ACTUAL'}}

2023-09-28